Several conditions treated as separate specialties share one driver. Recognising the shared mechanism changes what is worth treating first.
Polycystic ovary syndrome
PCOS is the most common endocrine dysfunction in women, affecting 10 to 20%. It is a lifelong condition with substantial medical, emotional and financial consequences, and it carries high risk for diabetes and metabolic syndrome.
It is fundamentally an insulin-resistance condition, which is why treatment aimed at insulin frequently improves the reproductive and dermatological features that brought the patient in — and why treatment aimed only at those features tends not to hold.
Non-alcoholic fatty liver disease
NAFLD is the main cause of liver disease. Its prevalence reaches roughly 30% in the general population and 75 to 100% in obesity, with varying degrees of severity. It is the hepatic expression of the same process: chronic hyperinsulinemia driving fat accumulation in an organ that was not intended to store it.
The liver’s congestion with fat is also part of why weight loss reverses diabetes — decongesting the liver and pancreas restores their function directly.
Inactivity as an independent trigger
A sedentary pattern is a core risk factor for diabetes, and the amount of inactivity required to produce measurable metabolic deterioration is smaller than most people assume. Short periods of enforced inactivity produce detectable changes in insulin sensitivity in healthy people, which reverse when activity resumes.
That cuts both ways and the encouraging half is worth stating: because the change is rapid in both directions, resuming activity produces measurable benefit quickly, well before any change in weight.
Comorbidity and mortality
The death rate in patients carrying multiple comorbid conditions of metabolic dysfunction is vastly greater than in the general population. Given that fewer than 12.2% of the US population was free of significant metabolic dysfunction in 2009–2016, and fewer than 7% are on post-2021 criteria, the comorbid group is not a small subpopulation.
Medications including ACE inhibitors have a legitimate role in managing the consequences. They do not address the driver, and prescribing them without addressing it commits the patient to indefinite management of a condition that was, at an earlier stage, reversible.
